PIQ
0.205
36.7%
PEN
0.275
-24.7%
ARV
0.004
33.3%
ADX
0.019
-20.8%
MRQ
0.004
33.3%
RGT
0.046
-14.8%
MYE
0.45
32.4%
IDT
0.035
-14.6%
CMD
0.029
31.8%
VBS
0.15
-14.3%
EVR
0.005
25%
CCA
0.055
-12.7%
AMD
0.006
20%
M96
0.007
-12.5%
CCE
0.24
20%
PLC
0.007
-12.5%
WEC
0.18
20%
MEK
0.093
-11.4%
DBO
0.013
18.2%
SLD
0.465
-11.4%
NRX
0.013
18.2%
APC
0.008
-11.1%
PGM
0.026
18.2%
CDE
0.008
-11.1%
ADO
0.024
14.3%
HIQ
0.008
-11.1%
BTN
0.016
14.3%
PPY
0.008
-11.1%
CAE
0.032
14.3%
AGR
0.017
-10.5%
MRD
0.024
14.3%
KLV
0.051
-10.5%
PVT
0.016
14.3%
88E
0.019
-9.5%
RGL
0.008
14.3%
DSK
0.685
-9.3%
BTL
0.29
13.7%
GTE
0.01
-9.1%
NHU
0.1
13.6%
AEM
0.36
-8.9%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics has successfully manufactured and passed quality release testing

Arovella Therapeutics (ASX:ALA) has successfully manufactured and passed quality release testing for its lead product ALA-101 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240102/pdf/05z33l2t26k412.pdf #ALA #Cancer